Roche enters into a definitive agreement to acquire Telavant including rights to novel TL1A directed antibody (RVT-3101) for the treatment of inflammatory bowel disease from Roivant

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the entry into a definitive agreement to acquire Telavant Holdings, Inc. (Telavant), a Roivant company, owned by Roivant Sciences Ltd. and Pfizer Inc.. The agreement includes the development, manufacturing and commercialisation rights in the US and Japan for ...

Related Keywords

Switzerland ,Japan ,United States ,America ,Levi Garraway ,Kirti Pandey ,Simon Goldsborough ,Thomas Schinecker ,Loren Kalm ,Gastroenterol Hepatol ,Nathalie Altermatt ,Karsten Kleine ,Sileia Urech ,Rebekka Schnell ,Roche Group ,Head Of Global Product Development ,Genentech ,Pfizer Inc ,Roivant Sciences Ltd ,Pfizer ,Telavant Holdings Inc ,Davis Polk Wardwell ,Freshfields Bruckhaus Deringer ,Telavant Holdings ,Roivant Sciences ,Chief Medical Officer ,Global Product ,Hart Scott Rodino Antitrust Improvements Act ,Davis Polk ,Dow Jones Sustainability Indices ,Chugai Pharmaceutical ,Inflamm Bowel ,